Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07191457 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo

A NA study of Head Lice, sponsored by Oystershell.

Recruiting
Registry status
NA
Development phase
86
Enrollment target
1
Study location

NCT07191457 is a NA study of Head Lice that is actively recruiting participants, run by Oystershell. The registered enrollment target is 86 participants, below the 100-participant average among 5 other Head Lice trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07191457, a NA study of Head Lice, is actively recruiting participants, sponsored by Oystershell.

RECRUITING
Registry status
NA
Development phase
86 participants
Enrollment target
1
Study location

Study Summary

Compare efficacy and safety of Elimax Green Lotion Emogreen (RID SUper Max Solution) to that of Walgreens Lice Killing Shampoo against headlice in infested individuals. Involved subjects aged 6 months and older, of both genders, with a confirmed diagnosis of head lice infestation are included. Local and global tolerability, skin and eye irritation are monitored throughout the study. Any adverse events will be monitored and recorded.

Conditions Studied

Interventions

  • DEVICE Elimax Green Lotion with Emogreen
  • DRUG Walgreens Lice Killing Shampoo

Study Locations (1)

Oklahoma

  • LSRN Research - Enid

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2025-10-02
Est. Completion 2026-04-01
Phase NA

Sponsor

Oystershell

5 total trials

What the Registry Record Tells You About NCT07191457

The ClinicalTrials.gov registry entry for NCT07191457 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 5 other Head Lice trials with a reported enrollment target (14% lower). The listed sponsor is Oystershell, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head Lice appearing as the primary indexed condition, and to 2 interventions - of which Elimax Green Lotion with Emogreen is the first listed.

NCT07191457 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT07191457 about?

NCT07191457 is a clinical study titled "Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo". Compare efficacy and safety of Elimax Green Lotion Emogreen (RID SUper Max Solution) to that of Walgreens Lice Killing Shampoo against headlice in infested individuals. Involved subjects aged 6 months and older, of both genders, with a confirmed diagnosis of head lice infestation are included. Local...

What is the current status of trial NCT07191457?

This trial is currently recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2025-10-02. Estimated completion is 2026-04-01.

What conditions does trial NCT07191457 study?

This clinical trial studies the following conditions: Head Lice.

What interventions are being tested in trial NCT07191457?

The interventions under investigation include: Elimax Green Lotion with Emogreen (DEVICE), Walgreens Lice Killing Shampoo (DRUG).

Who is sponsoring clinical trial NCT07191457?

This trial is sponsored by Oystershell, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07191457 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head Lice

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.